Risk Of Developing Liver Cancer After HCV Treatment

Tuesday, June 2, 2015

Hepatitis C/Interview with Dr. Lebovics; What challenges do you think daclatasvir will face should it be approved for use in the US......

AJM Hepatitis C Resource Center - Hepatitis C Blog Presents:

An interview with Dr. Lebovics breaking down the key data presented at EASL 2015.

Topics include;
Ledipasvir/Sofosbuvir
Continued use of ribavirin in DAA therapies? Is ribavirin really necessary? 
Daclatasvir, Sofosbuvir, and Ribavirin Combination For HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence
What challenges do you think daclatasvir will face should it be approved for use in the US given the current availability of approved DAAs such as ledipasvir/sofosbuvir?
and more...........

Click here to begin



This blog is supported by Elsevier Multimedia Publishing and the American Journal of Medicine (AJM), and serves as a companion to their comprehensive, online, global educational initiative, the AJM Hepatitis C Resource Center (hepcresource.amjmed.com).

Recent posts

No comments:

Post a Comment